新型脱氢松香酸-1,2,3-三唑-噁唑烷酮杂交化合物的设计、合成和抗增殖性评价

IF 3.597 Q2 Pharmacology, Toxicology and Pharmaceutics MedChemComm Pub Date : 2024-01-11 DOI:10.1039/D3MD00550J
Yaju Wu, Lin Huang, Xianli Ma, Xiaoqun Zhou, Qian Li and Fangyao Li
{"title":"新型脱氢松香酸-1,2,3-三唑-噁唑烷酮杂交化合物的设计、合成和抗增殖性评价","authors":"Yaju Wu, Lin Huang, Xianli Ma, Xiaoqun Zhou, Qian Li and Fangyao Li","doi":"10.1039/D3MD00550J","DOIUrl":null,"url":null,"abstract":"<p >A series of novel dehydroabietic acid derivatives containing both 1,2,3-triazole and oxazolidinone <strong>4a–4t</strong> have been synthesized and their antiproliferative activity <em>in vitro</em> against HeLa, HepG2, MGC-803 and T-24 cell lines evaluated. Most of them displayed cell proliferation inhibition on four tested human malignant tumour cell lines to some degree. Among them, compound <strong>4p</strong> exhibited promising cytotoxicity with IC<small><sub>50</sub></small> values ranging from 3.18 to 25.31 μM and weak cytotoxicity toward normal cells. The mechanism of action of <strong>4p</strong> was then studied using flow cytometry, Hoechst 33258 staining, ROS generation assay, and JC-1 mitochondrial membrane potential staining, which illustrated that compound <strong>4p</strong> induced apoptosis, arrested mitotic process at the G1 phase of the cell cycle, reduced the mitochondrial membrane potential, and increased intracellular ROS levels. In summary, the introduction of an oxazolidinone group <em>via</em> a “1,2,3-triazole” linker significantly improved the antitumor activity of dehydroabietic acid, and deserves to be further investigated.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":null,"pages":null},"PeriodicalIF":3.5970,"publicationDate":"2024-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Design, synthesis, and antiproliferative evaluation of novel dehydroabietic acid-1,2,3-triazole-oxazolidinone hybrids†\",\"authors\":\"Yaju Wu, Lin Huang, Xianli Ma, Xiaoqun Zhou, Qian Li and Fangyao Li\",\"doi\":\"10.1039/D3MD00550J\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >A series of novel dehydroabietic acid derivatives containing both 1,2,3-triazole and oxazolidinone <strong>4a–4t</strong> have been synthesized and their antiproliferative activity <em>in vitro</em> against HeLa, HepG2, MGC-803 and T-24 cell lines evaluated. Most of them displayed cell proliferation inhibition on four tested human malignant tumour cell lines to some degree. Among them, compound <strong>4p</strong> exhibited promising cytotoxicity with IC<small><sub>50</sub></small> values ranging from 3.18 to 25.31 μM and weak cytotoxicity toward normal cells. The mechanism of action of <strong>4p</strong> was then studied using flow cytometry, Hoechst 33258 staining, ROS generation assay, and JC-1 mitochondrial membrane potential staining, which illustrated that compound <strong>4p</strong> induced apoptosis, arrested mitotic process at the G1 phase of the cell cycle, reduced the mitochondrial membrane potential, and increased intracellular ROS levels. In summary, the introduction of an oxazolidinone group <em>via</em> a “1,2,3-triazole” linker significantly improved the antitumor activity of dehydroabietic acid, and deserves to be further investigated.</p>\",\"PeriodicalId\":88,\"journal\":{\"name\":\"MedChemComm\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.5970,\"publicationDate\":\"2024-01-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"MedChemComm\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://pubs.rsc.org/en/content/articlelanding/2024/md/d3md00550j\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2024/md/d3md00550j","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

摘要

我们合成了一系列含有 1,2,3-三唑和噁唑烷酮 4a-4t 的新型脱氢松香酸衍生物,并评估了它们在体外对 HeLa、HepG2、MGC-803 和 T-24 细胞系的抗增殖活性。其中大多数化合物对四种受测人类恶性肿瘤细胞系都有一定程度的细胞增殖抑制作用。其中,化合物 4p 表现出良好的细胞毒性,IC50 值在 3.18 至 25.31 μM 之间,对正常细胞的细胞毒性较弱。研究人员随后使用流式细胞仪、Hoechst 33258 染色法、ROS 生成测定法和 JC-1 线粒体膜电位染色法对 4p 的作用机制进行了研究,结果表明化合物 4p 能诱导细胞凋亡,在细胞周期的 G1 阶段阻止有丝分裂过程,降低线粒体膜电位,并增加细胞内的 ROS 水平。总之,通过 "1,2,3-三唑 "连接物引入噁唑烷酮基团可显著提高脱氢松香酸的抗肿瘤活性,值得进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Design, synthesis, and antiproliferative evaluation of novel dehydroabietic acid-1,2,3-triazole-oxazolidinone hybrids†

A series of novel dehydroabietic acid derivatives containing both 1,2,3-triazole and oxazolidinone 4a–4t have been synthesized and their antiproliferative activity in vitro against HeLa, HepG2, MGC-803 and T-24 cell lines evaluated. Most of them displayed cell proliferation inhibition on four tested human malignant tumour cell lines to some degree. Among them, compound 4p exhibited promising cytotoxicity with IC50 values ranging from 3.18 to 25.31 μM and weak cytotoxicity toward normal cells. The mechanism of action of 4p was then studied using flow cytometry, Hoechst 33258 staining, ROS generation assay, and JC-1 mitochondrial membrane potential staining, which illustrated that compound 4p induced apoptosis, arrested mitotic process at the G1 phase of the cell cycle, reduced the mitochondrial membrane potential, and increased intracellular ROS levels. In summary, the introduction of an oxazolidinone group via a “1,2,3-triazole” linker significantly improved the antitumor activity of dehydroabietic acid, and deserves to be further investigated.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
MedChemComm
MedChemComm BIOCHEMISTRY & MOLECULAR BIOLOGY-CHEMISTRY, MEDICINAL
CiteScore
4.70
自引率
0.00%
发文量
0
审稿时长
2.2 months
期刊介绍: Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry. In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.
期刊最新文献
Back cover Introduction to the themed collection on ‘AI in Medicinal Chemistry’ Back cover Rationally modified SNX-class Hsp90 inhibitors disrupt extracellular fibronectin assembly without intracellular Hsp90 activity† Design, synthesis and biological evaluation of a novel PSMA–PI3K small molecule drug conjugate†
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1